# Plain Language Summary: Protecting Americans from Unsafe Drugs Act of 2023

Right now, the FDA has strong powers to quickly recall medications that contain controlled substances (like opioids or other drugs that can be abused) if they're found to be unsafe or contaminated. This bill expands those same recall powers to cover all other drugs—things like antibiotics, blood pressure medications, diabetes drugs, and over-the-counter medicines. Basically, it removes the distinction between controlled and non-controlled drugs when it comes to the FDA's ability to pull dangerous medications off the market fast.

Here's why this matters in practical terms: if a batch of blood pressure medication gets contaminated with something harmful, or if a manufacturer discovers a serious safety problem with their antibiotic, the FDA would be able to act just as quickly and decisively as they do with controlled substances. Right now, the process for recalling non-controlled drugs might be slower or less straightforward. This bill streamlines that process so any dangerous drug can be removed from shelves and prevented from being distributed before it reaches patients. It also clarifies that these same recall rules apply to drugs being imported into or exported from the United States.

The bill essentially treats all medications equally when it comes to safety emergencies. If you take any kind of prescription or over-the-counter medication, this could mean faster protection if a serious problem is discovered. The FDA would have clearer authority to act immediately rather than going through a longer process, potentially preventing harm to people who might otherwise take a contaminated or defective drug.

Protecting Americans from Unsafe Drugs Act of 2023

Kim, Andy

Protecting Americans from Unsafe Drugs Act of 2023 This bill expands the authority of the Secretary of the Department of Health and Human Services (HHS) to order the recall of controlled substances to cover all drugs. Furthermore, the authority to issue such an order may be delegated to the Director of the Center for Drug Evaluation and Research or the Director of the Center for Biologics Evaluation and Research (or an official senior to either director), whereas currently this authority may only be delegated to the Director of the Center for Drug Evaluation and Research or an official senior to such director. (Both centers are located in the Food and Drug Administration within HHS.)